1)Polman CH, et al ; AFFIRM Investigators : A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9) : 899-910, 2006. PMID 16510744
2)Yamamura T, et al : Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381(22) : 2114-2124, 2019. PMID 31774956
3)Traboulsee A, et al : Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder ; a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 19(5) : 402-412, 2020. PMID 32333898
4)Cree BAC, et al ; N-MOmentum study investigators : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum) ; a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 394(10206) : 1352-1363, 2019. PMID 31495497
5)Ryerson LZ, et al : Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 93(15) : e1452-e1462, 2019. PMID 31515290
6)Ryerson LZ, et al : No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing ; real-world evidence from MS PATHS. Mult Scler Relat Disord 58 : 103480, 2022. PMID 35051898